Related Research Articles
Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials.
Dendrimers are highly ordered, branched polymeric molecules. Synonymous terms for dendrimer include arborols and cascade molecules. Typically, dendrimers are symmetric about the core, and often adopt a spherical three-dimensional morphology. The word dendron is also encountered frequently. A dendron usually contains a single chemically addressable group called the focal point or core. The difference between dendrons and dendrimers is illustrated in the top figure, but the terms are typically encountered interchangeably.
Nanobiotechnology, bionanotechnology, and nanobiology are terms that refer to the intersection of nanotechnology and biology. Given that the subject is one that has only emerged very recently, bionanotechnology and nanobiotechnology serve as blanket terms for various related technologies.
Nanochemistry is an emerging sub-discipline of the chemical and material sciences that deals with the development of new methods for creating nanoscale materials. The term "nanochemistry" was first used by Ozin in 1992 as 'the uses of chemical synthesis to reproducibly afford nanomaterials from the atom "up", contrary to the nanoengineering and nanophysics approach that operates from the bulk "down"'. Nanochemistry focuses on solid-state chemistry that emphasizes synthesis of building blocks that are dependent on size, surface, shape, and defect properties, rather than the actual production of matter. Atomic and molecular properties mainly deal with the degrees of freedom of atoms in the periodic table. However, nanochemistry introduced other degrees of freedom that controls material's behaviors by transformation into solutions. Nanoscale objects exhibit novel material properties, largely as a consequence of their finite small size. Several chemical modifications on nanometer-scaled structures approve size dependent effects.
Drug delivery refers to approaches, formulations, manufacturing techniques, storage systems, and technologies involved in transporting a pharmaceutical compound to its target site to achieve a desired therapeutic effect. Principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are used to optimize efficacy and safety, and to improve patient convenience and compliance. Drug delivery is aimed at altering a drug's pharmacokinetics and specificity by formulating it with different excipients, drug carriers, and medical devices. There is additional emphasis on increasing the bioavailability and duration of action of a drug to improve therapeutic outcomes. Some research has also been focused on improving safety for the person administering the medication. For example, several types of microneedle patches have been developed for administering vaccines and other medications to reduce the risk of needlestick injury.
Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.
Magnetofection is a transfection method that uses magnetic fields to concentrate particles containing vectors to target cells in the body. Magnetofection has been adapted to a variety of vectors, including nucleic acids, non-viral transfection systems, and viruses. This method offers advantages such as high transfection efficiency and biocompatibility which are balanced with limitations.
Photothermal therapy (PTT) refers to efforts to use electromagnetic radiation for the treatment of various medical conditions, including cancer. This approach is an extension of photodynamic therapy, in which a photosensitizer is excited with specific band light. This activation brings the sensitizer to an excited state where it then releases vibrational energy (heat), which is what kills the targeted cells.
Lipid nanoparticles (LNPs) are nanoparticles composed of lipids. They are a novel pharmaceutical drug delivery system, and a novel pharmaceutical formulation. LNPs as a drug delivery vehicle were first approved in 2018 for the siRNA drug Onpattro. LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle.
The applications of nanotechnology, commonly incorporate industrial, medicinal, and energy uses. These include more durable construction materials, therapeutic drug delivery, and higher density hydrogen fuel cells that are environmentally friendly. Being that nanoparticles and nanodevices are highly versatile through modification of their physiochemical properties, they have found uses in nanoscale electronics, cancer treatments, vaccines, hydrogen fuel cells, and nanographene batteries.
Nanoparticles for drug delivery to the brain is a method for transporting drug molecules across the blood–brain barrier (BBB) using nanoparticles. These drugs cross the BBB and deliver pharmaceuticals to the brain for therapeutic treatment of neurological disorders. These disorders include Parkinson's disease, Alzheimer's disease, schizophrenia, depression, and brain tumors. Part of the difficulty in finding cures for these central nervous system (CNS) disorders is that there is yet no truly efficient delivery method for drugs to cross the BBB. Antibiotics, antineoplastic agents, and a variety of CNS-active drugs, especially neuropeptides, are a few examples of molecules that cannot pass the BBB alone. With the aid of nanoparticle delivery systems, however, studies have shown that some drugs can now cross the BBB, and even exhibit lower toxicity and decrease adverse effects throughout the body. Toxicity is an important concept for pharmacology because high toxicity levels in the body could be detrimental to the patient by affecting other organs and disrupting their function. Further, the BBB is not the only physiological barrier for drug delivery to the brain. Other biological factors influence how drugs are transported throughout the body and how they target specific locations for action. Some of these pathophysiological factors include blood flow alterations, edema and increased intracranial pressure, metabolic perturbations, and altered gene expression and protein synthesis. Though there exist many obstacles that make developing a robust delivery system difficult, nanoparticles provide a promising mechanism for drug transport to the CNS.
Christine Allen is a Canadian professor and the first associate vice-president and vice-provost for strategic initiatives at the University of Toronto. She served formerly as interim dean of the university's Leslie Dan Faculty of Pharmacy. She is co-founder of Nanovista, a company focused on imaging of tumors. She also works as the associate editor of Molecular Pharmaceutics.
Ijeoma Uchegbu is a Nigerian-British Professor of Pharmacy at University College London, where she held the position of Pro-Vice Provost for Africa and the Middle East. She is the Chief Scientific Officer of Nanomerics, a pharmaceutical nanotechnology company specialising in drug delivery solutions for poorly water-soluble drugs, nucleic acids and peptides. She is also a Governor of the Wellcome, a large biomedical research charity. Apart from her highly cited scientific research in Pharmaceutical Nanoscience, Uchegbu is also known for her work in science public engagement and equality and diversity in Science, Technology, Engineering and Mathematics (STEM). In December 2023, it was announced that she will become President of Wolfson College, Cambridge, in October 2024.
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
Hamid Ghandehari is an Iranian-American drug delivery research scientist, and a professor in the Departments of Pharmaceutics and Pharmaceutical Chemistry and Biomedical Engineering at the University of Utah. His research is focused in recombinant polymers for drug and gene delivery, nanotoxicology of dendritic and inorganic constructs, water-soluble polymers for targeted delivery and poly(amidoamine) dendrimers for oral delivery.
Helen M. Burt is a British-Canadian pharmaceutical scientist who is the Angiotech Professor of Drug Delivery at the University of British Columbia. She serves as Associate Vice President of Research and Innovation at UBC. Her research considers novel therapeutics based on nanotechnology, including drug delivery systems for the treatment of bladder cancer and coronary artery disease.
Chitosan-poly is a composite that has been increasingly used to create chitosan-poly(acrylic acid) nanoparticles. More recently, various composite forms have come out with poly(acrylic acid) being synthesized with chitosan which is often used in a variety of drug delivery processes. Chitosan which already features strong biodegradability and biocompatibility nature can be merged with polyacrylic acid to create hybrid nanoparticles that allow for greater adhesion qualities as well as promote the biocompatibility and homeostasis nature of chitosan poly(acrylic acid) complex. The synthesis of this material is essential in various applications and can allow for the creation of nanoparticles to facilitate a variety of dispersal and release behaviors and its ability to encapsulate a multitude of various drugs and particles.
Reduction-sensitive nanoparticles (RSNP) consist of nanocarriers that are chemically responsive to reduction. Drug delivery systems using RSNP can be loaded with different drugs that are designed to be released within a concentrated reducing environment, such as the tumor-targeted microenvironment. Reduction-Sensitive Nanoparticles provide an efficient method of targeted drug delivery for the improved controlled release of medication within localized areas of the body.
Protein nanotechnology is a burgeoning field of research that integrates the diverse physicochemical properties of proteins with nanoscale technology. This field assimilated into pharmaceutical research to give rise to a new classification of nanoparticles termed protein nanoparticles (PNPs). PNPs garnered significant interest due to their favorable pharmacokinetic properties such as high biocompatibility, biodegradability, and low toxicity Together, these characteristics have the potential to overcome the challenges encountered with synthetic NPs drug delivery strategies. These existing challenges including low bioavailability, a slow excretion rate, high toxicity, and a costly manufacturing process, will open the door to considerable therapeutic advancements within oncology, theranostics, and clinical translational research.
Alexander Viktorovich Kabanov, is a Russian and American chemist, an educator, an entrepreneur, and a researcher in the fields of drug delivery and nanomedicine.
References
- ↑ Baas, Jeroen; Boyack, Kevin; Ioannidis, John P.A. (2021). "August 2021 data-update for 'Updated science-wide author databases of standardized citation indicators'". Elsevier Data Repository. 3. doi: 10.17632/btchxktzyw.3 .
- ↑ "Leadership". SMDG.
- ↑ "Invited speakers". CESPT 2023.
- 1 2 3 4 "Staff Profile School of Pharmacy Newcastle University". ncl.ac.uk.
- 1 2 "Nanomedicine Editorial Board". Nanomedicine.
- 1 2 "M. Moghimi". USERN .
- 1 2 "Nano-drugs are bad news for diseases". University Post. 30 November 2001.
- ↑ Moghimi, S. Moein (2015). "Meet Our Editorial Board Member". Current Pharmaceutical Biotechnology. 16 (10): 851–852. doi:10.2174/138920101610150810121628.
- ↑ "Nanotechnology Now - News Story: Denmark funds nanotechnology". nanotech-now.
- ↑ "Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology". EurekAlert!.
- ↑ Moghimi, S. (December 2020). "The Journal of Nanotheranostics: A New Open-Access Journal at the Interface of Nanotechnology, Materials Science, and Medicine for Precision Medicine". Journal of Nanotheranostics. 1 (1): 56–57. doi: 10.3390/jnt1010005 . ISSN 2624-845X.
- ↑ "Molecular Therapy editorial board contacts". Cell.com.
- ↑ "Editorial board".
- ↑ "Editorial board ADDR". sciencedirect.com.
- ↑ "Editorial board - JCR". www.sciencedirect.com.
- ↑ Moghimi, S. Moein; Hunter, A. Christy; Murray, J. Clifford (March 2005). "Nanomedicine: current status and future prospects". The FASEB Journal. 19 (3): 311–330. doi: 10.1096/fj.04-2747rev . ISSN 0892-6638. PMID 15746175. S2CID 30173777.
- ↑ Moghimi, Seyed M.; Simberg, Dmitri; Anchordoquy, Thomas J. (March 2020). "Tuning the Engines of Nanomedicine". Molecular Therapy. 28 (3): 693–694. doi:10.1016/j.ymthe.2020.01.025. PMC 7054826 . PMID 32032534.
- ↑ "Cancer gene therapy from camels". ScienceDaily.
- ↑ "Plastic cubes injected into the body could replace booster shots". New Scientist.
- ↑ "Study: How to keep nanoparticle caterpillars safe from the crows of the immune system". EurekAlert!.
- ↑ Papini, E.; Tavano, R.; Mancin, F. (2020). "Opsonins and Dysopsonins of Nanoparticles: Facts, Concepts, and Methodological Guidelines". Frontiers in Immunology. 11: 567365. doi: 10.3389/fimmu.2020.567365 . PMC 7587406 . PMID 33154748.
- ↑ Moghimi, S.M; Patel, H.M (June 1998). "Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system – The concept of tissue specificity". Advanced Drug Delivery Reviews. 32 (1–2): 45–60. doi:10.1016/s0169-409x(97)00131-2. PMID 10837635.
- ↑ Moghimi, S.M; Muir, I.S; Illum, L; Davis, S.S; Kolb-Bachofen, V (November 1993). "Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1179 (2): 157–165. doi:10.1016/0167-4889(93)90137-e. PMID 8218358.
- ↑ Moghimi, S.M.; Porter, C.J.H.; Muir, I.S.; Illum, L.; Davis, S.S. (June 1991). "Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating". Biochemical and Biophysical Research Communications. 177 (2): 861–866. doi:10.1016/0006-291x(91)91869-e. PMID 2049107.
- ↑ Moghimi, S. M.; Hawley, A. E.; Christy, N. M.; Gray, T.; Illum, L.; Davis, S. S. (1994-05-09). "Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes". FEBS Letters. 344 (1): 25–30. Bibcode:1994FEBSL.344...25M. doi: 10.1016/0014-5793(94)00351-3 . PMID 8181558. S2CID 31767077.
- ↑ Wu, Lin-Ping; Ahmadvand, Davoud; Su, Junan; Hall, Arnaldur; Tan, Xiaolong; Farhangrazi, Z. Shadi; Moghimi, S. Moein (2019-10-11). "Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide". Nature Communications. 10 (1): 4635. Bibcode:2019NatCo..10.4635W. doi:10.1038/s41467-019-12554-2. PMC 6789111 . PMID 31604928.
- ↑ "Realising The Potential of Nanomedicine - Formulation & Delivery Approaches". Oxford Global.
- ↑ "Beyond the Barrier". The Medicine Maker. 2019-11-12.
- ↑ "7 Molecular Therapy classics to read for ASGCT 2017". crosstalk.cell.com.
- ↑ Moghimi, S. M.; Symonds, P.; Murray, J. C.; Hunter, A. C.; Debska, G.; Szewczyk, A. (June 2006). "A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy". Molecular Therapy: The Journal of the American Society of Gene Therapy. 11 (6): 990–995. doi: 10.1016/j.ymthe.2005.02.010 . PMID 15922971.
- ↑ Moghimi, S.M (July 1997). "Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo?". Biochimica et Biophysica Acta (BBA) - General Subjects. 1336 (1): 1–6. doi:10.1016/s0304-4165(97)00060-3. PMID 9271243.
- ↑ Moghimi, S M; Hedeman, H; Christy, N M; Ilium, L; Davis, S S (1 December 1993). "Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats". Journal of Leukocyte Biology. 54 (6): 513–517. doi:10.1002/jlb.54.6.513. PMID 8245702. S2CID 42780562.
- ↑ Sim, Robert B.; Wallis, Russell (February 2011). "Immune attack on nanoparticles". Nature Nanotechnology. 6 (2): 80–81. doi:10.1038/nnano.2011.4. PMID 21293484.
- ↑ Salmaso, Stefano; Caliceti, Paolo (7 March 2013). "Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers". Journal of Drug Delivery. 2013: 1–19. doi: 10.1155/2013/374252 . PMC 3606770 . PMID 23533769.
- ↑ Hamad, I.; Hunter, A.C.; Szebeni, J.; Moghimi, S.M. (December 2008). "Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process". Molecular Immunology. 46 (2): 225–232. doi:10.1016/j.molimm.2008.08.276. PMID 18849076.
- ↑ de Vrieze, Jop (8 March 2021). "Suspicions grow that nanoparticles in Pfizer's COVID-19 vaccine trigger rare allergic reactions". ScienceInsider. doi:10.1126/science.abg2359.
- ↑ Moghimi, S.M. (September 2014). "Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth". Journal of Controlled Release. 190: 556–562. doi:10.1016/j.jconrel.2014.03.051. PMID 24746624.
- ↑ Wibroe, Peter P.; Mat Azmi, Intan D.; Nilsson, Christa; Yaghmur, Anan; Moghimi, S. Moein (November 2015). "Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers". Nanomedicine. 11 (8): 1909–1914. doi:10.1016/j.nano.2015.08.003. PMID 26348655.
- ↑ Wibroe, Peter Popp; Anselmo, Aaron C.; Nilsson, Per H.; Sarode, Apoorva; Gupta, Vivek; Urbanics, Rudolf; Szebeni, Janos; Hunter, Alan Christy; Mitragotri, Samir; Mollnes, Tom Eirik; Moghimi, Seyed Moein (June 2017). "Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes". Nature Nanotechnology. 12 (6): 589–594. Bibcode:2017NatNa..12..589W. doi:10.1038/nnano.2017.47. hdl: 10037/13642 . PMID 28396605.
- ↑ Moghimi, Seyed Moein (May 2018). "Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions". Drug Discovery Today. 23 (5): 1034–1042. doi:10.1016/j.drudis.2017.11.006. PMID 29146517.
- ↑ Wu, Lin-Ping; Ficker, Mario; Christensen, Jørn B.; Simberg, Dmitri; Trohopoulos, Panagiotis N.; Moghimi, Seyed M. (11 August 2021). "Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking". Nature Communications. 12 (1): 4858. Bibcode:2021NatCo..12.4858W. doi:10.1038/s41467-021-24960-6. PMC 8357934 . PMID 34381048.
- ↑ Moghimi, S. M.; Simberg, D.; Anchordoquy TJ (2020). "Tuning the Engines of Nanomedicine". Molecular Therapy. 28 (3): 693–694. doi:10.1016/j.ymthe.2020.01.025. PMC 7054826 . PMID 32032534.
| International | |
|---|---|
| Other | |
